ArticleNature communications2026
Large language model driven multicenter prediction and explainable risk attribution of acute kidney injury.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) represents a life-threatening condition among hospitalized patients, where early prediction enables prevention. Despite advances in existing models, clinical implementation remains hindered by excessive false positive rates (70%-94%) and lack of actionable clinical insights. We conduct a multi-center retrospective cohort study and develop a two-model large language model framework: AKI-PM (Prediction Model) for predicting AKI occurrence within 24 hours and AKI-RAM (Risk Attribution Model) for providing explainable risk attribution. Using a cohort of 140,637 hospital admissions across four geographically diverse Chinese hospitals, we demonstrate that AKI-PM achieves high predictive performance in internal validation (area under curve 0.95, positive predictive value 0.68) and maintains robust generalizability across external sites after few-shot (area under curve 0.92-0.96, positive predictive value 0.69-0.74). Crucially, AKI-RAM provides structured, clinically actionable risk explanations by distinguishing modifiable from non-modifiable factors and offering tailored recommendations. In a clinical evaluation of 200 cases from four independent hospitals by six nephrologists, AKI-RAM receives high scores across eight dimensions (Likert scale: 4.18-4.88) with moderate to good inter-rater reliability (intraclass correlation coefficients: 0.680-0.803). This integrated framework addresses critical limitations in AI-driven clinical prediction by combining accuracy with interpretability, offering a scalable solution for early AKI prevention in diverse healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.